Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Clin Med pulm > Tuberculosis > Flashcards

Tuberculosis Flashcards

1
Q

Mycobacterium tuberculosis:

A

doesn’t gram stain

-culture takes 2-3 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

TB info:

A

1/3 of world pop. is infected

*** leading cause of death in HIV pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

TB risk factors:

A

Close contacts of persons known or suspected to have active TB
Foreign-born persons from areas where TB is common
Populations with increased incidence of latent M. tuberculosis infection or TB disease, such as homeless, IVDA, HIV patients
Residents or health care workers (HCWs) exposed to high-risk patients (hospitals, homeless shelters, prisons, nursing homes, etc)
Children < 5yo with positive TB test
People who are immunocompromised (HIV, substance abuse, diabetes, silicosis, severe kidney disease, low body weight, organ transplant recipients, head/neck cancer patients, steroid treatment, RA or Crohn’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

TB transmission:

A
  • spread via airborne droplet nuclei
  • 1-3 bacilli per droplet
  • remains in air for hours
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TB pathogenesis:

A
  • droplet inhaled and travels to alveoli where it multiplies
  • some enter bloodstream and travel to other areas such as brain
  • normally contained within 2-8 weeks by body. if not it spreads
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Latent TB infection (LTBI)

A
  • can stay latent or can breakdown and produce TB disease
  • Latent detected via TST or interferon-gamma release assay
  • LTBI pts are not infectious
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Active TB:

A
  • 10% of patients
  • can occur soon after infections or years later
  • can spread disease
  • positive cultures confirm diagnosis
  • reactivation occurs within 2 years in 50% of infected pts.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Most common site of TB:

A
  • Lungs (usually infectious)
  • Apices most common site of reactivation
  • Caseating granulomas
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Miliary TB:

A

Bacilli can spread to all parts of body, and fatal if untreated
-Millet seed appearance on CXR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CNS TB:

A

-usually occurs as meningitis, but can occur in brain or spine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

GHON complex

A
  • radiodense area on CXR
  • stable granuloma
  • found in 20% of LTBI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

extra pulmonary TB:

A

usually not infectious, unless person has
Concomitant pulmonary disease,
Extrapulmonary disease in the oral cavity or larynx, or
Extrapulmonary disease with open site, especially with aerosolized fluid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

who should be tested:

A

Contacts of persons known or suspected to have infectious TB disease
People who have come to the United States within the last 5 years from areas of the world where TB is common (ex: Asia, Africa, Eastern Europe, Latin America, and Russia)
Persons who visit areas of the world where TB is common
People who live or work in congregate settings whose clients are at increased risk for TB disease
Health care workers who serve clients who are at increased risk for TB disease
Populations defined as high risk for LTBI or active TB disease, such as medically underserved, low-income persons, or persons who abuse drugs or alcohol
Infants, children, and adolescents exposed to adults at increased risk for infection or disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

testing methods for TB infection in US:

A

Mantoux tuberculin skin test (TST)
Interferon Gamma Release Assays (IGRAs):
QuantiFERON-TB Gold In-Tube (QFT-GIT)®, and
T-Spot.TB®

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

administering TST:

A 
Inject 0.1 ml of PPD (5 tuberculin units) into forearm at 5 – 15 degree angle between skin layers 
Produce wheal (raised area) 6–10 mm in diameter
Follow universal precautions for infection control
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Reading TST:

A

Trained health care worker assesses reaction 48–72 hours after injection
Palpate injection site to find raised area
Measure diameter of induration across forearm; only measure induration, not redness
Record size of induration in millimeters; record “0” if no induration found

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

≥5 mm induration is classified as positive in

A

HIV-infected persons
Recent contacts of infectious TB
Persons with fibrotic changes on chest radiograph consistent with prior TB
Patients with organ transplants and other immunosuppressed patients

18
Q

≥10 mm induration is classified as positive in

A

Recent arrivals from high-prevalence countries
Injection drug users
Residents and employees of high-risk congregate settings
Mycobacteriology laboratory personnel
Persons with conditions that increase risk for progressing to TB
Children <5 years of age, or children and youth exposed to adults at high risk

19
Q

≥15 mm is classified as positive in

A

Persons with no known risk factors for TB

20
Q

Interferon Gamma Release Assays (IGRAs)

A

IGRAs detect M. tb infection by measuring immune response in blood
Cannot differentiate between TB and LTBI
other tests needed
May be used for surveillance/screening, or to find those who will benefit from treatment
FDA-approved IGRAs are QFT Gold In-Tube and T- Spot.TB test

21
Q

Evaluation of Persons with Positive TB Tests

A

Facilities should consult with local health department before starting testing program to ensure evaluation and treatment resources are available
Persons with positive test should be evaluated for disease
If disease is ruled out, consider for LTBI treatment
If patient not willing or able to take treatment, educate on TB signs and symptoms

22
Q

BCG Vaccination:

A

Vaccine made from live, attenuated (weakened) strain of M. bovis
Early version first given to humans in 1921
Many TB-prevalent countries vaccinate infants to prevent severe TB disease
BCG not generally recommended in the U.S.
Use BCG only after consultation with local health department and TB experts

23
Q

Interpretation of TB Test Results in BCG-Vaccinated Persons

A

TST or IGRA not contraindicated for BCG-vaccinated persons
Results used to support or exclude diagnosis of infection
In BCG-vaccinated, interpret TST with same criteria used for non BCG vaccinated

24
Q

Who should be evaluated for TB?

A

Cough lasting more than 3 weeks
Unexplained wt loss
Hemoptysis

Additional symptoms: fever, chills, night sweats

25
Q

Medical Evaluation for TB

A 
Medical history
Physical examination
Test for TB infection
Chest radiograph
Bacteriologic examination
26
Q

Medical Hx:

A

Symptoms of disease; how long
History of TB exposure, infection, or disease
Past TB treatment
Demographic risk factors for TB
Medical conditions that increase risk for TB disease

27
Q

Symptoms of pulmonary TB:

A 
Prolonged productive cough (3 weeks or longer)
Hemoptysis
Loss of appetite
Unexplained weight loss
Night sweats, fever
Fatigue
Chest pain
28
Q

Symptoms of possible extrapulmonary TB:

A 
Blood in the urine (TB of the kidney)
Headache/confusion (TB meningitis)
Back pain (TB of the spine)
Hoarseness (TB of the larynx)
Loss of appetite, unexplained weight loss
Night sweats, fever
Fatigue
29
Q

Physical Examination of TB:

A

Provides valuable information about the patient’s overall condition
Cannot be used to confirm or rule out TB disease
May have dullness to percussion, rales, increased vocal fremitus

30
Q

CBC with TB:

A

elevated WBC

31
Q

CXR with TB:

A

Chest abnormalities suggest, but do not confirm, TB disease
Posterior-anterior view is standard
Apical/posterior areas of upper lobe or superior areas of lower lobe often show patchy or nodular infiltrates
May see cavitation with air-fluid levels as infection progresses
In immunosuppressed (e.g., HIV infected), lesions may have atypical appearance
Less likely to have + TST or fever

32
Q

HIV pts pulmonary TB may have atypical radiograph:

A

Less common: cavitary disease (with higher CD4 counts)
More common: infiltrates, adenopathy, or normal radiograph (with lower CD4 counts)
With signs/symptoms, negative radiograph does not rule out disease
With no signs/symptoms and positive TB test, negative radiograph may rule out TB in HIV-negative person

33
Q

Testing/ specimens:

A 
Specimen collection
AFB smear classification
NAA testing
Culture and identification
Drug-susceptibility testing
34
Q

Specimen collection, processing, and review

A

All persons suspected of TB disease should have sputum cultured
Collect at least 3 sputum specimens at 8- to 24-hour intervals, at least 1 in the morning
Follow infection control precautions during specimen collection
Collection methods include coughing, sputum induction, bronchoscopy, gastric aspiration

35
Q

First evidence of mycobacteria in testing come from:

A

detecting AFB in smears

  • results in 24
  • provides preliminary presumptive diagnosis of TB
36
Q

Nucleic Acid Amiplification testing in TB:

A

NAA tests rapidly identify a specimen via DNA and RNA amplification
Benefits may include
Earlier lab confirmation of TB disease
Earlier respiratory isolation and treatment initiation
Improved patient outcomes; interruption of transmission
Perform at least 1 NAA test on each pulmonary TB suspect
A single negative NAA test does not exclude TB

37
Q

*Gold Standard for confirming TB:

A

Culture

  • culture all specimens even if smear or NAA is negative
  • 4-14 days
  • culture monthly until 2 consecutive negative cultures
38
Q

Drug-susceptibility testing:

A

Conduct drug-susceptibility testing on initial M. tb isolate
Promptly forward results to the health department
Repeat for patients who
Do not respond to therapy or
Have positive cultures despite 3 months of therapy

39
Q

New TB test: XPERT MTB/RIF Assay:

A

Test detects M. tb complex and rifampin resistance simultaneously
Results in 2 hrs
Sputum sample

40
Q

TB 1st Line drugs:

A 
Isoniazid
Rifampin
Pyrazinamide
Ethambutol
Rifabutin*
Rifapentine
  • = Not approved by the U.S. Food and Drug Administration for use in the treatment of TB
41
Q

Second line TB drugs:

A 
Streptomycin
Cycloserine
p-Aminosalicylic acid
Ethionamide
Amikacin or kanamycin*
Capreomycin
Levofloxacin*
Moxifloxacin*
Gatifloxacin*

*= Not approved by the U.S. Food and Drug Administration for use in the treatment of TB

42
Q

RIPE=

A

Rifampin/rifapentine
Isoniazid
Pyrazinamide
Ethambutol

Clin Med pulm (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions